Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neurocrine Biosciences reports strong Q4 performance and eyes growth

Neurocrine Biosciences delivered strong performance in Q4 2022, with robust INGREZZA sales and a positive outlook for 2023, supported by significant investments in SG&A and R&D.
The company's focus on expanding into long-term care, advancing pipeline assets, and collaborations for innovative treatments positions it well for growth and addressing unmet needs.
While facing challenges in managing increased spending and market dynamics, Neurocrine remains optimistic about opportunities in expanding treatment reach, market penetration, and advancing clinical programs.

Neurocrine Biosciences reports strong Q1 performance and eyes international expansion

Neurocrine Biosciences had a strong Q1 performance with record sales, upcoming milestones, and disciplined expense management.
The company faces challenges in certain therapeutic categories but is optimistic about addressing unmet needs and expanding internationally.
Opportunities lie in innovative science, market positioning, and portfolio expansion, positioning Neurocrine for future growth.
Addressing concerns around drug interactions, dosing strategies, and trial risks will be crucial for maintaining clinical success and patient safety.

Neurocrine Biosciences excels in Q2, eyes growth opportunities ahead

Neurocrine Biosciences shows strong financial performance and growth prospects.
Focus on INGREZZA's persistency and pipeline advancements drives optimism.
Challenges include market dynamics and clinical trial complexities.
Opportunities lie in new indications, long-term care expansion, and telemedicine.

Neurocrine Biosciences excels in Q3, eyes growth in LTC segment

Neurocrine Biosciences delivered a strong Q3 performance with robust sales, positive regulatory developments, and promising pipeline advancements.
The company's focus on expanding indications, exploring combination therapies, and addressing market opportunities positions it for future growth.
While facing challenges in market evaluation and competition, Neurocrine Biosciences has opportunities to leverage its strengths and drive innovation.
Investors can look forward to upcoming events like the Analyst Day and R&D Day for deeper insights into the company's strategic direction and growth potential.

Neurocrine Biosciences excels in 2023, eyes Crinecerfont launch success

Neurocrine Biosciences had a strong 2023 with notable achievements in sales growth and pipeline advancements. While facing challenges in market dynamics and pricing negotiations, the company is well-positioned to leverage opportunities in upcoming launches and strategic growth initiatives.

Neurocrine Biosciences excels in Q1 with strong sales and pipeline advancements

Neurocrine Biosciences delivered a strong performance in Q1 2024, driven by robust INGREZZA sales, promising Phase II results for NBI-845, and advancements in Crinecerfont development.
The company's strengths lie in its diverse pipeline, financial stability, and strategic focus on chronic therapy and tolerability, positioning it for future growth and innovation.
While facing challenges in dosing optimization and revenue management, Neurocrine has opportunities to leverage its pipeline, explore new treatments, and differentiate its offerings in the market.

Neurocrine Biosciences excels in Q3, poised for growth ahead

Neurocrine Biosciences showcased robust performance in Q3, with strong INGREZZA sales and pipeline success, positioning for future growth.
The company's strengths lie in its expanded sales team, leadership quality, and commitment to innovation and value creation for shareholders.
Challenges include potential payer reimbursement issues, FDA interactions for Phase III strategy, and competitive pressures in the market.
Opportunities abound with upcoming regulatory approvals, pipeline advancements, and targeted commercial strategies for new product launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Catalent

CTLT vs. NBIX: Which Stock Is the Better Value Option?

CTLT or NBIX: Which Is the Better Value Stock Right Now?

HKMPF vs. NBIX: Which Stock Is the Better Value Option?

HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?

Neurocrine (NBIX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why Neurocrine (NBIX) Could Be Positioned for a Surge

Ingrezza sales came in well ahead of expectations as management continues to execute well with its commercial launch in this under-penetrated market.

Neurocrine Executing Very Well With Its Lead Commercial Compound

Neurocrine (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Neurocrine (NBIX) Might be Well Poised for a Surge

Sales soared for the drug Ingrezza. And key pipeline developments are on the way.

Neurocrine Biosciences Posts Sizzling Sales Growth in Q2

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2019 Results - Earnings Call Transcript

Neurocrine (NBIX) delivered earnings and revenue surprises of 54.17% and 14.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates

Neurocrine (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Neurocrine (NBIX) Ahead of Earnings?

Axon Enterprise

American Homes 4 Rent

Etsy

Palo Alto Networks

Block

Tandem Diabetes Care

Neurocrine Biosciences, Facebook and Etsy are just some of the stocks to buy if you want growth because they're outpacing Amazon.

8 Stocks to Buy That Are Growing Faster Than Amazon

American Express

Chesapeake Energy

Domo

Gilead Sciences

Invitation Homes

Nabors Industries

PG&E

Penn Entertainment

Uber

Morgan Stanley has identified the stocks with the most positive momentum going into the 2Q 2019 earnings reporting season.

10 Stocks with Upside Momentum for 2Q Earnings

The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.

FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug

Neurocrine reported better than expected sales of Ingrezza, but the Street may still obsess over weak-looking sequential prescription growth in a seasonally tougher quarter.

Neurocrine Drifting, But The Total Package Is Still Appealing

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2019 Results - Earnings Call Transcript

A midsize acquisition seems imminent, and these two would fit like a glove.

2 Biotech Takeout Targets Perfect for Biogen: Neurocrine Biosciences

Since my earlier article, Neurocrine Biosciences shares have retreated quite a bit off all time highs in September 2018.

Neurocrine Biosciences: Rapid Pipeline Expansion Underway

Data from a small Phase II study suggest NBI-74788 is effective in reducing biomarkers tied to CAH and doing so safely.

News for Neurocrine Biosciences Stock (NBIX)